The Chemours Company Reports Third Quarter Results

Chemours posts strong Q3 profit surge, driven by pricing and segment growth.

What the company is saying

Chemours reports Q3 2026 net sales of $1.5 billion, up 3% year-over-year, highlighting a 10% pricing increase in Titanium Technologies and 26% growth in APM Performance Solutions. Net income attributable to Chemours rose to $196 million, or $1.29 per diluted share, from $46 million, or $0.31 per share, a year earlier. Adjusted EBITDA increased to $200 million, up from $189 million, with management attributing gains to pricing power in TT and a favorable mix shift toward APM Performance Solutions. The company emphasizes strategic progress, including a $150 million PFAS insurance proceeds receipt tied to a New Jersey consent order, a settlement with North Carolina and 11 local entities over PFAS litigation, and the $340 million sale of the Kuan Yin property. CEO Denise Dignam frames results as evidence of strong execution in TT and APM, citing demand from AI infrastructure and data center markets. The launch of the Faizeon™ liquid cooling portfolio is positioned as a step into high-value end markets, though no financial impact is disclosed.

What the data suggests

Q3 2026 net sales reached $1.5 billion, up 3% year-over-year, with a 5% price increase offsetting a 2% volume decline and minor currency headwind. Net income attributable to Chemours was $196 million, or $1.29 per diluted share, versus $46 million and $0.31 per share last year, a result that includes a $150 million PFAS insurance proceeds benefit. Adjusted net income was $31 million, or $0.21 per share, up from $26 million and $0.17 per share. Adjusted EBITDA rose to $200 million from $189 million, driven by TT pricing and APM mix, despite lower TSS volumes and higher costs. Segment results show TT net sales up 11% to $680 million and adjusted EBITDA up 240% to $85 million, APM net sales up 8% to $337 million and adjusted EBITDA up 71% to $24 million, while TSS net sales fell 9% to $510 million and adjusted EBITDA dropped 30% to $136 million. Free cash flow was $98 million, with operating cash flows of $149 million. Gross debt stands at $3.9 billion, net debt at $3.2 billion, and liquidity at $1.7 billion. The company forecasts Q4 net sales to decline 5–10% sequentially, with adjusted EBITDA of $160–185 million, and expects 2026 net sales up 2% over 2025 and adjusted EBITDA of $775–800 million.

Analysis

The announcement is largely factual and supported by detailed, realised financial and operational data for Q3 2026, including net sales, net income, adjusted EBITDA, segment performance, and cash flow. The tone is positive, but the language is proportionate to the results, with no evidence of narrative inflation or exaggerated claims. Forward-looking statements (guidance for Q4 and full-year 2026) are clearly separated from realised results and are not presented as already-achieved. The only qualitative claims lacking quantifiable detail are the impact of settlements and the new product launch, but these are not overstated. There is no evidence of a large capital outlay paired with only long-dated, uncertain returns; capital expenditures are moderate and matched by immediate financial results. The gap between narrative and evidence is minimal.

Risk flags

• ●Chemours' net leverage ratio remains elevated at 4.3x, with $3.2 billion in net debt, which increases sensitivity to earnings volatility or adverse legal outcomes.
• ●The $150 million PFAS insurance proceeds and Kuan Yin property sale are one-time items that inflate current quarter results and will not recur, potentially masking underlying operational trends.
• ●TSS segment performance is under pressure, with net sales down 9% and adjusted EBITDA down 30% year-over-year, primarily due to lower North American stationary AC aftermarket volumes and higher costs.
• ●Legal and regulatory risks persist, as evidenced by ongoing PFAS-related settlements in multiple states, which could lead to further cash outflows or operational constraints.
• ●Q4 guidance anticipates sequential declines in net sales and EBITDA for key segments, reflecting ongoing market softness and seasonality, which could pressure near-term profitability.

Bottom line

Chemours delivered a strong Q3, with net income surging to $196 million and adjusted EBITDA up to $200 million, primarily on the back of robust pricing in Titanium Technologies and growth in APM Performance Solutions. The quarter benefited from a $150 million insurance proceeds windfall and the $340 million Kuan Yin property sale, both of which are non-recurring. While TT and APM segments posted notable gains, TSS performance weakened, and overall leverage remains high at 4.3x net. The company faces ongoing legal and regulatory risks from PFAS litigation, and Q4 guidance points to sequential declines in most segments due to seasonality. Investors should focus on the sustainability of pricing gains, the ability to manage leverage, and the impact of further legal settlements. The most important takeaway is that while Q3 results are strong, much of the upside is driven by one-off items, and underlying operational momentum is mixed across segments.

Announcement summary

(NYSE:CC) The Chemours Company reported third quarter 2026 net sales of $1.5 billion, representing a 3% increase compared to the prior-year quarter, driven by a 5% increase in pricing and partially offset by a 2% decrease in volumes and a slight currency headwind. Net income attributable to Chemours was $196 million, or $1.29 per diluted share, compared to $46 million, or $0.31 per diluted share, in Q3 2025. Adjusted net income was $31 million, or $0.21 per diluted share, up from $26 million, or $0.17 per diluted share, in the prior-year quarter. Adjusted EBITDA for the quarter was $200 million, compared to $189 million in Q3 2025, driven by improved pricing in Titanium Technologies (TT) and growth in Advanced Performance Materials (APM) Performance Solutions. The company received $150 million related to PFAS insurance proceeds in connection with the finalization of the judicial consent order with the State of New Jersey, presented as a reduction to selling, general, and administrative expense. Chemours entered into a settlement with the State of North Carolina and 11 local entities to resolve litigation relating to PFAS and other historical discharges from Fayetteville Works, as well as claims of PFAS contamination unrelated to that site. The company completed the sale of the Kuan Yin property for total net consideration of approximately $340 million, including the remaining land parcel for $56 million of gross proceeds. In the Thermal & Specialized Solutions (TSS) segment, Q3 2026 net sales were $510 million, down 9% year-over-year, with adjusted EBITDA of $136 million and an adjusted EBITDA margin of 27%. In the TT segment, net sales were $680 million, up 11% year-over-year, with adjusted EBITDA of $85 million and an adjusted EBITDA margin of 13%. The APM segment reported net sales of $337 million, up 8% year-over-year, with adjusted EBITDA of $24 million and an adjusted EBITDA margin of 7%. Corporate expenses were $46 million in Q3 2026. As of September 30, 2026, consolidated gross debt was $3.9 billion, with net debt of $3.2 billion and a net leverage ratio of approximately 4.3x. Total liquidity was $1.7 billion, including $698 million in unrestricted cash and $953 million of revolving credit facility capacity. Operating cash flows for Q3 2026 were $149 million, including the $150 million PFAS insurance proceeds and offset by approximately $100 million in settlement payments and $25 million in taxes related to the Kuan Yin property sale. Capital expenditures for the quarter were $51 million, and free cash flows were $98 million. For Q4 2026, Chemours expects consolidated net sales to decrease 5% to 10% sequentially, with adjusted EBITDA between $160 million and $185 million, corporate expenses of $40 million to $45 million, and capital expenditures between $75 million and $85 million. For full year 2026, the company expects net sales to grow approximately 2% over 2025, adjusted EBITDA between $775 million and $800 million, capital expenditures between $220 million and $230 million, and free cash flow conversion above 15%. Chemours anticipates achieving a net leverage ratio below 4.2x in 2026. The company formally launched its Faizeon™ liquid cooling portfolio, including four two-phase direct-to-chip and one immersion cooling fluid. Denise Dignam, President and CEO, stated that the results reflect strong performance in TT and APM, pricing execution in TiO2, and increased demand in high-value AI infrastructure, and highlighted progress on strategic priorities including settlements and asset sales.

Disagree with this article?